Esperion Therapeutics, Inc. (ESPR)
(Delayed Data from NSDQ)
$27.68 USD
-0.87 (-3.05%)
Updated Feb 25, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank | Definition | Annualized Return |
---|---|---|
1 | Strong Buy | 24.41% |
2 | Buy | 17.88% |
3 | Hold | 9.48% |
4 | Sell | 5.03% |
5 | Strong Sell | 1.87% |
S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value Score | A |
---|---|
Growth Score | A |
Momentum Score | A |
VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value C Growth D Momentum D VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Zacks News
Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.
MRKPositive Net Change CANFNegative Net Change USNAPositive Net Change ESPRNegative Net Change
earnings pharmaceuticals
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -3.46% and -49.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
ESPRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More
by Kinjel Shah
Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.
ARNANegative Net Change JAZZNegative Net Change HALONegative Net Change ESPRNegative Net Change EPZMNegative Net Change
biotechs
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down
by Zacks Equity Research
Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.
SNYNegative Net Change MRKPositive Net Change AMGNNegative Net Change ESPRNegative Net Change
pharmaceuticals
Why Is Esperion Therapeutics (ESPR) Up 17.5% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ESPRNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.
MRKPositive Net Change EBSNegative Net Change HZNPNegative Net Change ESPRNegative Net Change
earnings pharmaceuticals
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.78% and 4.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ESPRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Earnings Preview: Esperion Therapeutics (ESPR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ESPRNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Esperion Therapeutics (ESPR) Up 12.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ESPRNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.
MRKPositive Net Change EBSNegative Net Change HZNPNegative Net Change ESPRNegative Net Change
biotechs
Esperion Therapeutics (ESPR) Beats Q2 Earnings Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 102.82% and -0.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ESPRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Why Is Esperion Therapeutics (ESPR) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ESPRNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
All You Need to Know About Esperion Therapeutics (ESPR) Rating Upgrade to Buy
by Zacks Equity Research
Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ESPRNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Esperion (ESPR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging first-quarter results. The company records product revenues for the first time during the quarter.
SNYNegative Net Change MRKPositive Net Change AMGNNegative Net Change ESPRNegative Net Change
earnings pharmaceuticals
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 9.55% and 91.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ESPRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Tilray (TLRY) in Focus: Stock Moves 9.6% Higher
by Zacks Equity Research
Tilray (TLRY) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
ESPRNegative Net Change TLRYNegative Net Change
medical
Esperion's Cholesterol Drugs Receive Approval in Europe
by Zacks Equity Research
Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.
REGNNegative Net Change SNYNegative Net Change MRKPositive Net Change ESPRNegative Net Change
biotechs
Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ESPRNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.
SNYNegative Net Change MRKPositive Net Change AMGNNegative Net Change ESPRNegative Net Change
earnings pharmaceuticals
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 16.61% and 1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ESPRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ESPRNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Esperion's Promising Drugs Under Review, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.
MRKPositive Net Change SNYNegative Net Change REGNNegative Net Change ESPRNegative Net Change
pharmaceuticals
Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%
by Zacks Equity Research
Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
ESPRNegative Net Change IRWDNegative Net Change
medical
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results.
MRKPositive Net Change ACORNegative Net Change VRTXNegative Net Change ESPRNegative Net Change
earnings pharmaceuticals
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -25.37% and 5.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ESPRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank